Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis

Europace

Volumn 18, Issue 5, 2016, Pages 665-671

  Chan, Pak Hei ^a   Huang, Duo ^a   Yip, Pok Siu ^b   Hai, Jojo ^a   Tse, Hung Fat ^a   Chan, Tak Mao ^a   Lip, Gregory Y H ^c   Lo, Wai Kei ^b   Siu, Chung Wah ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b TUNG WAH HOSPITAL   (Hong Kong)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atrial fibrillation; Chronic kidney disease; Ischaemic stroke; Peritoneal dialysis

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC PATIENT; CHADS2 SCORE; CHINESE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; VISUAL ANALOG SCALE; COMPARATIVE STUDY; COMPLICATION; HONG KONG; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; REGISTER; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; FEMALE; HONG KONG; HOSPITALIZATION; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; STROKE; WARFARIN;

EID: 84975223708     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv289     Document Type: Article

References (49)

1. Lau CP, Tse HF, Siu CW, Gbadebo D. Atrial electrical and structural remodeling: implications for racial differences in atrial fibrillation. J Cardiovasc Electrophysiol 2012; 23(Suppl 1):S36-40.
2. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan Wet al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2011;4:26-32.
3. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123:2946-53.
4. Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi KE et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5:173-81.
5. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:1102-7.
6. Atar I, Konas D, Acikel S, Kulah E, Atar A, Bozbas H et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol 2006; 106:47-51.
7. Genovesi S, Pogliani D, Faini A, Valsecchi MG, Riva A, Stefani F et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005;46:897-902.
8. Wetmore JB, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int 2012;81:469-76.
9. Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, IsraelCWet al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-A position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015;17:1169-96.
10. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363-9.
11. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol 2003;4:1.
12. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-33.
13. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011;6:2662-8.
14. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 2007;50:433-40.
15. Biggers JA, Remmers AR Jr., Glassford DM, Sarles HE, Lindley JD, Fish JC. The risk of anticoagulation in hemodialysis patients. Nephron 1977;18:109-13.
16. Siu CW, Lip GY, Lam KF, Tse HF. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm 2014;11:1401-8.
17. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012;125:2298-307.
18. Ho LY, Siu CW, Yue WS, Lau CP, Lip GY, Tse HF. Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension. J Hum Hypertens 2011;25:304-10.
19. Siu CW, Jim MH, Ho HH, Miu R, Lee SW, Lau CP et al. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. Chest 2007;132:44-9.
20. Siu CW, Jim MH, Lau CP, Tse HF. Low molecular weight heparin versus unfractionated heparin for thromboprophylaxis in patients with acute atrial fibrillation: a randomized control trial. Acute Card Care 2011;13:196-8.
21. Chong BH, Chan KH, Pong V, Lau KK, Chan YH, Zuo ML et al. Use of aspirin in Chinese after recovery from primary intracranial haemorrhage. Thromb Haemost 2012;107:241-7.
22. Teo KC, Mahboobani NR, Lee R, Siu CW, Cheung RT, Ho SL et al.Warfarin associated intracerebral hemorrhage in Hong Kong Chinese. Neurol Res 2014;36: 143-9.
23. Chan KH, Ka-Kit Leung G, Lau KK, Liu S, Lui WM, Lau CP et al. Predictive value of the HAS-BLED score for the risk of recurrent intracranial hemorrhage after first spontaneous intracranial hemorrhage. World Neurosurg 2014;82:e219-23.
24. Pong V, Chan KH, Chong BH, Lui WM, Leung GK, Tse HF et al. Long-term outcome and prognostic factors after spontaneous cerebellar hemorrhage. Cerebellum 2012; 11:939-45.
25. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500-10.
26. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124.
27. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014;129:1196-203.
28. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014;64:2471-82.
29. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367: 625-35.
30. Chao TF, Liu CJ,Wang KL, Lin YJ, Chang SL, Lo LWet al. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. J Am Coll Cardiol 2014;64:1658-65.
31. Siu CW. One more "C" for CHA2DS2-VASC score? J Am Coll Cardiol 2015;65: 1602-3.
32. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014;111:789-97.
33. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation 2011;124:314-23.
34. SiuCW, Pong V, Zhang X, Chan YH, Jim MH, Liu S et al. Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism. Heart Rhythm 2009;6: 169-73.
35. Wong LK. Global burden of intracranial atherosclerosis. Int J Stroke 2006;1:158-9.
36. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013;127:224-32.
37. Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM et al. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 2013;61:2079-87.
38. Roldan V, Marin F, Manzano-Fernandez S, Fernandez H, Gallego P, Valdes M et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013;109:956-60.
39. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Europace 2012;14:1385-413.
40. Hart RG, Pearce LA, AsingerRW, Herzog CA.Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011;6:2599-604.
41. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098-106.
42. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011;80:572-86.
43. Shiff B, Pierrato A, Oliver MJ, Jain AK, McCormick B, KandasamyG et al. Knowledge, attitudes, and practices with regard to PD access: a report from the Peritoneal Dialysis Access Subcommittee of the Ontario Renal Network Committee on Independent Dialysis. Perit Dial Int 2014;34:791-5.
44. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007;147:590-2.
45. Lai KN, Yin JA, Yuen PM, Li PK. Effect of hemodialysis on protein C, protein S, and antithrombin III levels. Am J Kidney Dis 1991;17:38-42.
46. Kim SB, Yang WS, Lee SK, Chi HS, Park JS. Effect of increasing serum albumin on haemostatic factors synthesized in the liver in CAPD patients. Nephrol, Dial, Transplant 1998;13:2053-8.
47. Clyne N, Egberg N, Lins LE. Effects of hemodialysis and long-term erythropoietin treatment on protein C, and on free and total protein S. Thromb Res 1995;80: 161-8.
48. Lai KN, Yin JA, Yuen PM, Li PK. Protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis and hemodialysis. Nephron 1990;56:271-6.
49. Bertoli SV, di Belgiojoso GB, Trezzi M, Scorza D, Barone MT, Poggio M et al. Reduced blood levels of coagulation inhibitors in chronic hemodialysis compared with CAPD. Adv Perit Dial 1995;11:127-30.